Sharon Velez-Maymi, MD
Endocrinology, Diabetes & Metabolism · San Juan, PRNPI 1982937728
Payments from drug & device makers
Across 135 payments — averaging $31.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$928
- Boehringer Ingelheim$512
- Novo Nordisk$382
- Johnson & Johnson$336
- Sanofi-aventis U.S. LLC$302
- Bayer$240
- plus $2K from 16 others
What the payments were for
- Food & beverage$4,19498%
- Education$712%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $928 |
| Boehringer Ingelheim | 19 | $512 |
| Novo Nordisk | 14 | $382 |
| Johnson & Johnson | 7 | $336 |
| Sanofi-aventis U.S. LLC | 16 | $302 |
| Bayer | 7 | $240 |
| Bayer Puerto Rico Inc. | 8 | $215 |
| E.r. Squibb & Sons, L.L.C. | 5 | $193 |
| Merck | 3 | $187 |
| AbbVie(2 entities) | 2 | $130 |
| GSK | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Kyowa Kirin, Inc. | 1 | $103 |
| Medtronic | 3 | $76 |
| Rhythm Pharmaceuticals, Inc. | 1 | $75 |
| Abbott | 3 | $73 |
| Biohaven Pharmaceuticals, Inc. | 2 | $55 |
| PBG Puerto Rico LLC | 2 | $50 |
| Revance Therapeutics, Inc. | 1 | $50 |
| Amgen | 2 | $47 |
| Dexcom, Inc. | 2 | $41 |
| Eli Lilly Export S.A. Puerto Rico Branch | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,265 in reported general payments places this provider in the 45th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
See all endocrinology, diabetes & metabolism providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 397 | $399,735 |
| Xigduo XrDapaglifloz Propaned/Metformin | 286 | $211,657 |
| FarxigaDapagliflozin Propanediol | 242 | $160,698 |
| JardianceEmpagliflozin | 116 | $93,062 |
| TrulicityDulaglutide | 84 | $87,882 |
| SynthroidLevothyroxine Sodium | 1,447 | $81,316 |
| SynjardyEmpagliflozin/Metformin Hcl | 99 | $66,861 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 86 | $64,875 |
| ForteoTeriparatide | 12 | $51,891 |
| MounjaroTirzepatide | 37 | $41,203 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $39,758 |
| LantusInsulin Glargine,hum.Rec.Anlog | 249 | $27,551 |
| ProliaDenosumab | 13 | $22,797 |
| RybelsusSemaglutide | 21 | $20,187 |
| HumalogInsulin Lispro | 153 | $18,929 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $382 | $419,922418 claims |
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Glyxambi, Tradjenta | $512 | $252,292339 claims |
| AstraZenecaFarxiga | $928 | $160,698242 claims |
| AbbVieSynthroid | $130 | $81,3161,447 claims |
| MerckJanumet Xr, Januvia, Janumet | $187 | $37,85755 claims |
| Sanofi-aventis U.S. LLCLantus, Soliqua 100-33 | $302 | $37,609260 claims |
| AmgenProlia | $47 | $22,79713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
Other endocrinology, diabetes & metabolism in San Juan
- Alex Gonzalez BossoloSan Juan$5.5M
- Martha GomezSan Juan$3.8M
- Michelle Mangual GarciaSan Juan$743K
- Loida Gonzalez RodriguezSan Juan$246K
- Manuel Alegre-HernandezSan Juan$156K
- Monica Ortiz-RiveraSan Juan$148K
- Oscar Ruiz BermudezSan Juan$94K
- Meliza Martinez RodriguezSan Juan$80K
- Jorge de Jesus MirandaSan Juan$30K
- Zahira Lugo LopezSan Juan$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.